Postmarketing Monitoring of Intussusception After RotaTeq Vaccination-United States, February 1, 2006 - February 15, 2007
This article, published in Morbidity and Mortality Weekly Report, summarizes the Advisory Committee on Immunization Practices review of post-marketing safety surveillance data on RotaTeq®, the rotavirus vaccine by Merck & Co., Inc. The data reveal that cases of intussusception reported since its introduction in early 2006 did not exceed the expected background rate.
Author(s): US Centers for Disease Control and Prevention
Visit web page (English)
(Located at www.cdc.gov)